EPS for uniQure N.V. (QURE) Expected At $-0.63

October 14, 2018 - By Adrian Mccoy

uniQure N.V. (NASDAQ:QURE) Logo

Analysts expect uniQure N.V. (NASDAQ:QURE) to report $-0.63 EPS on November, 7.They anticipate $0.23 EPS change or 57.50 % from last quarter’s $-0.4 EPS. After having $-0.57 EPS previously, uniQure N.V.’s analysts see 10.53 % EPS growth. The stock increased 2.48% or $0.69 during the last trading session, reaching $28.53. About 312,569 shares traded or 7.67% up from the average. uniQure N.V. (NASDAQ:QURE) has risen 408.66% since October 14, 2017 and is uptrending. It has outperformed by 393.04% the S&P500.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 7 analysts covering uniQure NV (NASDAQ:QURE), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure NV had 7 analyst reports since May 7, 2018 according to SRatingsIntel. The stock of uniQure N.V. (NASDAQ:QURE) earned “Buy” rating by Wells Fargo on Wednesday, May 16. The stock of uniQure N.V. (NASDAQ:QURE) has “Buy” rating given on Monday, September 24 by H.C. Wainwright. Chardan Capital Markets maintained uniQure N.V. (NASDAQ:QURE) on Wednesday, May 23 with “Buy” rating. The stock of uniQure N.V. (NASDAQ:QURE) earned “Buy” rating by Leerink Swann on Monday, May 7.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.06 billion. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

Another recent and important uniQure N.V. (NASDAQ:QURE) news was published by Globenewswire.com which published an article titled: “uniQure to Participate in Multiple Upcoming Industry Conferences” on September 28, 2018.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>